Variables . | All (N = 1,135) . |
---|---|
Male | 651 (57) |
Age (years) | 64 ± 11 |
BMI (kg/m2) | 31 ± 6 |
Active smoking | 125 (11) |
Known diabetes duration (years) | 14 ± 10 |
History of | |
Cardiovascular disease | 216 (19) |
Stroke | 61 (5) |
Myocardial infarction | 171 (15) |
Blood pressure (mmHg) | |
Systolic | 132 ± 18 |
Diastolic | 72 ± 11 |
Resting heart rate (bpm) | 71 ± 13 |
Therapeutics | |
Any antihypertensive drug | 950 (84) |
Diuretics | 504 (44) |
RAAS blockers | 711 (63) |
β-Blockers | 388 (34) |
Calcium antagonists | 418 (37) |
Any antidiabetic drug | 1,091 (96) |
Insulin | 683 (60) |
Oral antidiabetic agents | 740 (65) |
Biological determinations | |
HbA1c (%) | 7.8 ± 1.5 |
HbA1c (mmol/mol) | 62 ± 16.4 |
eGFR (mL/min/1.73 m2) | 76 ± 21 |
uACR (mg/mmol) | 2.6 (1.0–10.4) |
Normoalbuminuria* | 455 (45) |
Microalbuminuria* | 368 (36) |
Macroalbuminuria* | 187 (19) |
MR-proADM (nmol/L) | 0.72 (0.59–0.90) |
sTNFR1 (pg/mL) | 1,818 (1,544–2,231) |
NT-proBNP (pg/mL) | 101 (47–262) |
Biomarker risk score | 4.51 ± 0.45 |
Variables . | All (N = 1,135) . |
---|---|
Male | 651 (57) |
Age (years) | 64 ± 11 |
BMI (kg/m2) | 31 ± 6 |
Active smoking | 125 (11) |
Known diabetes duration (years) | 14 ± 10 |
History of | |
Cardiovascular disease | 216 (19) |
Stroke | 61 (5) |
Myocardial infarction | 171 (15) |
Blood pressure (mmHg) | |
Systolic | 132 ± 18 |
Diastolic | 72 ± 11 |
Resting heart rate (bpm) | 71 ± 13 |
Therapeutics | |
Any antihypertensive drug | 950 (84) |
Diuretics | 504 (44) |
RAAS blockers | 711 (63) |
β-Blockers | 388 (34) |
Calcium antagonists | 418 (37) |
Any antidiabetic drug | 1,091 (96) |
Insulin | 683 (60) |
Oral antidiabetic agents | 740 (65) |
Biological determinations | |
HbA1c (%) | 7.8 ± 1.5 |
HbA1c (mmol/mol) | 62 ± 16.4 |
eGFR (mL/min/1.73 m2) | 76 ± 21 |
uACR (mg/mmol) | 2.6 (1.0–10.4) |
Normoalbuminuria* | 455 (45) |
Microalbuminuria* | 368 (36) |
Macroalbuminuria* | 187 (19) |
MR-proADM (nmol/L) | 0.72 (0.59–0.90) |
sTNFR1 (pg/mL) | 1,818 (1,544–2,231) |
NT-proBNP (pg/mL) | 101 (47–262) |
Biomarker risk score | 4.51 ± 0.45 |
Data are mean ± SD, median (25th–75th percentile), or n (%).
History of cardiovascular disease was defined as history of stroke and/or myocardial infarction before baseline.
RAAS, renin-angiotensin-aldosterone system (angiotensin receptor blocker and/or ACE inhibitor).
*Normoalbuminuria was defined as uACR <30 mg/g, microalbuminuria as uACR 30–299 mg/g, and macroalbuminuria as uACR ≥300 mg/g